340 related articles for article (PubMed ID: 22017273)
21. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review.
Buttini MJ; Jordan SJ; Webb PM
Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):316-22. PubMed ID: 19566568
[TBL] [Abstract][Full Text] [Related]
22. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
Sturridge F; Guillebaud J
Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
[TBL] [Abstract][Full Text] [Related]
23. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
[TBL] [Abstract][Full Text] [Related]
24. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).
Sangkomkamhang US; Lumbiganon P; Pattanittum P
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD008994. PubMed ID: 33226133
[TBL] [Abstract][Full Text] [Related]
25. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.
Varma R; Sinha D; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):9-28. PubMed ID: 16325993
[TBL] [Abstract][Full Text] [Related]
26. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
[TBL] [Abstract][Full Text] [Related]
27. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis.
Elassall GM; Sayed EG; Abdallah NA; El-Zohiry MM; Radwan AA; AlMahdy AM; Sedik AS; Elazeem HASA; Shazly SA
J Gynecol Obstet Hum Reprod; 2022 Oct; 51(8):102432. PubMed ID: 35760334
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of the levonorgestrel intrauterine system (LNG-IUS) in the prevention of the atypical endometrial hyperplasia and endometrial cancer: retrospective data from selected obese menopausal symptomatic women.
Morelli M; Di Cello A; Venturella R; Mocciaro R; D'Alessandro P; Zullo F
Gynecol Endocrinol; 2013 Feb; 29(2):156-9. PubMed ID: 23134558
[TBL] [Abstract][Full Text] [Related]
29. Emerging indications for the levonorgestrel-releasing intrauterine system (LNG-IUS).
Heikinheimo O; Gemzell-Danielsson K
Acta Obstet Gynecol Scand; 2012 Jan; 91(1):3-9. PubMed ID: 22007693
[TBL] [Abstract][Full Text] [Related]
30. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
Krashin J; Tang JH; Mody S; Lopez LM
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD009805. PubMed ID: 26280888
[TBL] [Abstract][Full Text] [Related]
31. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis.
Conz L; Mota BS; Bahamondes L; Teixeira Dória M; Françoise Mauricette Derchain S; Rieira R; Sarian LO
Acta Obstet Gynecol Scand; 2020 Aug; 99(8):970-982. PubMed ID: 31990981
[TBL] [Abstract][Full Text] [Related]
32. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
[TBL] [Abstract][Full Text] [Related]
33. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
Ørbo A; Arnes M; Vereide AB; Straume B
BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
[TBL] [Abstract][Full Text] [Related]
34. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia.
van der Meer AC; Hanna LS
Clin Obes; 2017 Feb; 7(1):54-57. PubMed ID: 27984850
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia.
Bian J; Shao H; Liu H; Li H; Fang L; Xing C; Wang L; Tao M
Reprod Sci; 2015 Jun; 22(6):758-66. PubMed ID: 25536958
[TBL] [Abstract][Full Text] [Related]
36. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
[TBL] [Abstract][Full Text] [Related]
37. Malignant endometrial polyp in woman with the levonorgestrel intrauterine system - a case report.
Kuzel D; Mara M; Zizka Z; Koliba P; Dundr P; Fanta M
Gynecol Endocrinol; 2019 Feb; 35(2):112-114. PubMed ID: 30449212
[TBL] [Abstract][Full Text] [Related]
38. Continuous combined parenteral estrogen substitution and intrauterine progestogen delivery: the ideal HST combination?
Wildemeersch D; Janssens D; Weyers S
Maturitas; 2005 Jun; 51(2):207-14. PubMed ID: 15917162
[TBL] [Abstract][Full Text] [Related]
39. Why perimenopausal women should consider to use a levonorgestrel intrauterine system.
Wildemeersch D
Gynecol Endocrinol; 2016 Aug; 32(8):659-661. PubMed ID: 26930021
[TBL] [Abstract][Full Text] [Related]
40. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
